MVP
TEVA icon

Miller Value Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Miller Value Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,950
Closed -$241K – 37
2024
Q4 		$241K Hold
10,950
– – 0.1% 31
2024
Q3 		$197K Hold
10,950
– – 0.11% 29
2024
Q2 		$178K Sell
10,950
-650
-6% -$10K 0.11% 28
2024
Q1 		$164K Sell
11,600
-1,800
-13% -$22.7K 0.1% 30
2023
Q4 		$140K Sell
13,400
-825
-6% -$7.7K 0.08% 42
2023
Q3 		$145K Sell
14,225
-67,912
-83% -$632K 0.09% 45
2023
Q2 		$618K Sell
82,137
-3,847,647
-98% -$31.2M 0.41% 37
2023
Q1 		$34.8M Sell
3,929,784
-1,217,243
-24% -$12M 2.17% 23
2022
Q4 		$46.9M Sell
5,147,027
-4,107,848
-44% -$35.8M 3.03% 11
2022
Q3 		$74.7M Sell
9,254,875
-79,715
-0.9% -$705K 4.54% 4
2022
Q2 		$70.2M Sell
9,334,590
-724,149
-7% -$6.31M 3.57% 9
2022
Q1 		$94.5M Buy
10,058,739
+399,220
+4% +$3.33M 3.04% 8
2021
Q4 		$77.4M Sell
9,659,519
-88,610
-0.9% -$800K 2.12% 21
2021
Q3 		$94.9M Sell
9,748,129
-1,187,654
-11% -$11.1M 2.2% 12
2021
Q2 		$108M Buy
10,935,783
+381,718
+4% +$4.04M 2.58% 13
2021
Q1 		$122M Buy
10,554,065
+3,414,365
+48% +$39.2M 3.15% 6
2020
Q4 		$68.9M Sell
7,139,700
-953,998
-12% -$9.14M 2.1% 19
2020
Q3 		$72.9M Buy
8,093,698
+243,226
+3% +$2.57M 2.62% 11
2020
Q2 		$96.8M Sell
7,850,472
-67,890
-0.9% -$768K 4.3% 4
2020
Q1 		$71.1M Sell
7,918,362
-1,915,705
-19% -$19.6M 4.57% 2
2019
Q4 		$96.4M Buy
9,834,067
+1,342,915
+16% +$12M 3.42% 7
2019
Q3 		$58.4M Buy
8,491,152
+1,990,900
+31% +$15.3M 2.35% 19
2019
Q2 		$60M Buy
6,500,252
+1,957,720
+43% +$23.6M 2.28% 21
2019
Q1 		$71.2M Buy
4,542,532
+630,730
+16% +$11.1M 2.82% 16
2018
Q4 		$60.3M Buy
3,911,802
+6,350
+0.2% +$130K 2.74% 13
2018
Q3 		$84.1M Buy
3,905,452
+1,316,840
+51% +$30.6M 2.72% 14
2018
Q2 		$63M Buy
2,588,612
+393,640
+18% +$8.03M 2.35% 17
2018
Q1 		$37.5M Buy
2,194,972
+1,678,860
+325% +$32.8M 1.56% 29
2017
Q4 		$9.78M Buy
+516,112
New +$7.76M 0.42% 37

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Miller Value Partners's TEVA Position: Q1 2025 in Review

Miller Value Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 10,950 shares — an estimated $241K sold.

Miller Value Partners first reported a position in TEVA in Q4 2017 and held it in 29 quarters. The position peaked at $122M in Q1 2021. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Miller Value Partners reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Miller Value Partners sold 10,950 Teva Pharmaceuticals shares in Q1 2025, an estimated $241K.
  • Miller Value Partners first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 29 quarters.
  • Miller Value Partners's Teva Pharmaceuticals position peaked at $122M in Q1 2021.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Miller Value Partners's 13F filing for Q1 2025, filed 15 May 2025.